Legend Biotech Announces Participation in Upcoming Investor Conferences
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced it will participate in the upcoming investor conferences:
Event: Jefferies Healthcare Conference
Location: New York, NY
Fireside Chat Date & Time: Wednesday, June 7, 2023 at 1:30pm ET
Presenter: Ying Huang, Ph.D., CEO
Event: Goldman Sachs 44th Annual Global Healthcare Conference
Location: Dana Point, CA
Fireside Chat Date & Time: Wednesday, June 14, 2023 at 8:00am PT
Presenter: Ying Huang, Ph.D., CEO
About Legend Biotech
Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.
China and Kazakhstan have always supported each other and have always been partners in times of challenges, Chinese President Xi Jinping said in a signed article in the Kazakhstanskaya Pravda newspaper and Kazinform International News Agency on...
H.I.G. Capital ("H.I.G."), a leading global alternative investment firm with $64 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to acquire CGH Group S.A. ("CGH" or the "Company"), a...
Truecaller, the leading global platform for verifying contacts and blocking unwanted communication, is publishing its interim report for January-June on Friday 19 July 2024 at 07.30 CET.
Alan Mamedi, CEO and Odd Bolin, CFO presents the report and...
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...
China and Kazakhstan have always supported each other and have always been partners in times of challenges, Chinese President Xi Jinping said in a signed article in the Kazakhstanskaya Pravda newspaper and Kazinform International News Agency on...
